Atara Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Revenue	128.94	8.57	63.57	20.34	-	Upgrade
Revenue Growth (YoY)	1404.02%	-86.52%	212.55%	-	-	Upgrade
Cost of Revenue	168.74	228.05	269.99	282	244.65	Upgrade
Gross Profit	-39.8	-219.48	-206.42	-261.66	-244.65	Upgrade
Selling, General & Admin	38.53	49.8	68.13	78.8	64.4	Upgrade
Operating Expenses	38.53	49.8	68.13	78.8	64.4	Upgrade
Operating Income	-78.33	-269.28	-274.55	-340.46	-309.05	Upgrade
Interest Expense	-4.62	-5.29	-0.37	-	-	Upgrade
Interest & Investment Income	2.11	5.43	3.06	2.14	3.28	Upgrade
Other Non Operating Income (Expenses)	0.53	-0.25	-0.7	-	-	Upgrade
EBT Excluding Unusual Items	-80.31	-269.38	-272.56	-338.33	-305.78	Upgrade
Merger & Restructuring Charges	-5.11	-6.73	-5.96	-	-	Upgrade
Gain (Loss) on Sale of Investments	-	-	-	-1.77	-0.83	Upgrade
Gain (Loss) on Sale of Assets	-	-	50.24	-	-	Upgrade
Pretax Income	-85.42	-276.11	-228.29	-340.1	-306.61	Upgrade
Income Tax Expense	-0.01	0.02	0.01	0.05	0.02	Upgrade
Net Income	-85.4	-276.13	-228.3	-340.14	-306.62	Upgrade
Net Income to Common	-85.4	-276.13	-228.3	-340.14	-306.62	Upgrade
Shares Outstanding (Basic)	7	4	4	4	3	Upgrade
Shares Outstanding (Diluted)	7	4	4	4	3	Upgrade
Shares Change (YoY)	76.77%	3.83%	8.88%	26.63%	44.17%	Upgrade
EPS (Basic)	-11.41	-65.19	-55.96	-90.78	-103.63	Upgrade
EPS (Diluted)	-11.41	-65.19	-55.96	-90.78	-103.63	Upgrade
Free Cash Flow	-68.96	-194.2	-274.62	-231.1	-185.27	Upgrade
Free Cash Flow Per Share	-9.21	-45.84	-67.32	-61.68	-62.62	Upgrade
Gross Margin	-30.87%	-	-	-	-	Upgrade
Operating Margin	-60.75%	-3140.98%	-431.86%	-1673.85%	-	Upgrade
Profit Margin	-66.23%	-3220.88%	-359.12%	-1672.28%	-	Upgrade
Free Cash Flow Margin	-53.49%	-2265.25%	-431.98%	-1136.19%	-	Upgrade
EBITDA	-73.28	-264.45	-268.9	-331.12	-300.72	Upgrade
EBITDA Margin	-56.83%	-	-	-	-	Upgrade
D&A For EBITDA	5.05	4.83	5.65	9.35	8.33	Upgrade
EBIT	-78.33	-269.28	-274.55	-340.46	-309.05	Upgrade
EBIT Margin	-60.75%	-	-	-	-	Upgrade
Revenue as Reported	128.94	8.57	63.57	-	-	Upgrade

Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q